Capital International Investors Acquires 233,466 Shares of Xenon Pharmaceuticals Inc. $XENE

Capital International Investors lifted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 7.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 3,414,959 shares of the biopharmaceutical company’s stock after purchasing an additional 233,466 shares during the period. Capital International Investors’ holdings in Xenon Pharmaceuticals were worth $153,058,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in XENE. Danske Bank A S bought a new position in shares of Xenon Pharmaceuticals during the third quarter valued at approximately $32,000. Blue Trust Inc. raised its holdings in shares of Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 717 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new position in shares of Xenon Pharmaceuticals during the third quarter valued at approximately $39,000. Osaic Holdings Inc. raised its holdings in shares of Xenon Pharmaceuticals by 541.4% during the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,034 shares in the last quarter. Finally, State of Wyoming grew its stake in Xenon Pharmaceuticals by 112.8% in the third quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 610 shares during the period. Institutional investors own 95.45% of the company’s stock.

Insider Transactions at Xenon Pharmaceuticals

In other news, Director Gillian Cannon sold 1,190 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the sale, the director directly owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. This represents a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Ian Mortimer sold 7,308 shares of the stock in a transaction on Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $403,620.84. Following the completion of the sale, the chief executive officer directly owned 19,923 shares in the company, valued at approximately $1,100,347.29. This represents a 26.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 12,572 shares of company stock valued at $689,101. 4.07% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages recently weighed in on XENE. Stifel Nicolaus set a $66.00 price target on Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Wolfe Research began coverage on Xenon Pharmaceuticals in a research note on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price target on the stock. Morgan Stanley set a $97.00 price target on Xenon Pharmaceuticals in a research note on Monday, March 9th. Jefferies Financial Group set a $100.00 price target on Xenon Pharmaceuticals in a research note on Monday, March 9th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Xenon Pharmaceuticals has an average rating of “Buy” and a consensus target price of $77.20.

Xenon Pharmaceuticals Trading Down 1.0%

NASDAQ XENE opened at $51.21 on Tuesday. Xenon Pharmaceuticals Inc. has a 12 month low of $30.00 and a 12 month high of $63.95. The stock has a market cap of $4.95 billion, a P/E ratio of -10.90 and a beta of 0.62. The stock’s fifty day moving average price is $55.74 and its 200-day moving average price is $48.68.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same period in the previous year, the firm earned ($0.83) earnings per share. As a group, analysts forecast that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.